ClinicalTrials.Veeva

Menu

Intravenous Artesunate and Malaria (IVAS)

U

University of Khartoum

Status and phase

Unknown
Phase 4

Conditions

Malaria

Treatments

Drug: Quinine
Drug: artesunate

Study type

Interventional

Funder types

Other

Identifiers

NCT01805232
artesunate and malaria

Details and patient eligibility

About

Intravenous artesunate is egual to quinine in the treatment of severe malaria

Full description

Intravenous artesunate is egual to quinine in the treatment of severe malaria in the form of fever clearance time and parasite clearance time

Enrollment

80 estimated patients

Sex

All

Ages

1 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

severe P.falciparum malaria-

Exclusion criteria

mixed infection Pregnant women -

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

80 participants in 2 patient groups

artesunate
Experimental group
Description:
intravenous artesunate 80 mg/kg initially then after 8 hours then daily
Treatment:
Drug: Quinine
Drug: artesunate
quinine
Active Comparator group
Description:
quinine infusion 80 mg/kg every 8 hours
Treatment:
Drug: Quinine
Drug: artesunate

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems